GRO Network™ Brings Environmental Transparency to Grain Market
1.9.2020 15:30:00 EEST | Business Wire | Press release
Farmer’s Business Network, Inc. (FBNSM), the leading direct-to-farm ag tech platform and farmer network, today launched GRO Network™, which provides new technology and services that facilitate the scoring, sourcing, and pricing of Low-Carbon Grain from farm to fork, making environmental transparency in the grain industry a reality now.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005290/en/
GRO Network enables comprehensive environmental transparency, and supports a market for premium, environmentally-scored grain. GRO Network also provides buying intelligence software that directly connects farmers with consumer packaged goods companies, animal feed providers, biofuel makers and the world’s other major grain buyers.
POET, the world’s largest producer of biofuels has joined GRO Network as a key customer in the market for verifiable Low-Carbon Grain.
“Family farms have already invested the time, innovation and sweat-equity to develop the regenerative practices required to grow Low-Carbon Grain,” said Amol Deshpande, CEO and Co-Founder of FBN. “With GRO Network, the efforts of farmers as well as food and feed companies, biofuel makers, and ordinary consumers to reduce carbon emissions just got a huge boost.”
Transparency in the agriculture supply chain starts with data direct from the field.
Farmers share information on their cultivation practices - including fertilizer applications, tillage, and cover cropping - with GRO Network, which is processed with artificial intelligence that leverage FBN’s 240 million acre-events of real world farm data, validates and distills the practices into a single farm-level score. This single score - which is the only information shared between GRO Network and prospective buyers - informs the buyer to then source premium grain as well as build programs to meet unique sustainability goals, while protecting farmers’ data privacy.
Importantly, verifiable Low-Carbon Grain will allow agricultural processors and food companies to meet their own significant emission goals. Policymakers will be able to evaluate a precise, farm-level carbon-intensity score to more accurately measure the GHG reduction of biofuels for low carbon fuel policies. GRO Network will help these companies embed the required carbon traceability into their supply chains, all within the current government policy framework.
“At POET we know that agriculture is the key to combating climate change, and we want to support farmers who share our mission to be good stewards of the earth by using environmentally friendly practices,” said POET Founder and CEO Jeff Broin. “We are excited about the potential of the GRO Network to promote sustainable agriculture and utilize the resulting Low-Carbon Corn to produce even greener bioethanol and bioproducts.”
GRO Network is focusing initially on carbon abatement, which, based on GRO Network pilots, can reduce grain emissions by up to 50%, while increasing farm revenues at the same time. It relies on proven, existing science and robust FBN analytics to measure the benefits of conservation activities on the farm, providing immediate, low-risk solutions to reduce the environmental impact of the agriculture supply chain.
“Regenerative agriculture techniques have not only saved us money, they’ve made us money,” said Todd Hanten, who farms 3,000 acres of corn, soybeans and spring wheat in South Dakota. “We’ve always tried these practices side by side and can compare conventional tillage to no-till and strip till and we’ve realized the benefits through our data analytics. We’re happy to find out that the practices we’ve adopted are saving us money and making us a better return.”
FBN began development of GRO Network close to two years ago in order to allow fuel, food and feed companies to work alongside farmers to accelerate the adoption of regenerative agricultural practices that deliver the biggest impact. GRO Network incentivizes sustainable conservation and soil health practices by producers, ensuring a consistent supply of high quality, Low-Carbon Grain for buyers.
“Ultimately, GRO Network aligns farmers, processors, brands, consumers and policy-makers in the fight against climate change,” Deshpande said. “We are excited to see family farm incomes improve as a direct result.”
Learn more at www.fbngro.com
About FBN:
Farmer’s Business Network, Inc. is an independent ag tech platform and farmer-to-farmer network with a mission to power the prosperity of family farmers around the world, while working towards a sustainable future. Its Farmers First® promise has attracted over 14,000 members to the network with a common goal of maximizing their farm’s profit potential. FBN has set out to redefine value and convenience for farmers by helping reduce the cost of production and maximize the value of their crops.
The FBN network has grown to cover more than 40 million acres of member farms in the U.S., Canada and Australia. Blending the best of Midwestern agricultural roots and Silicon Valley technology, the company has over 600 personnel and offices in San Carlos, Calif., Chicago, Sioux Falls, S.D., a Canadian headquarters in High River, Alta., and an Australian headquarters in Perth.
To learn more, visit: www.fbn.com.
Copyright ©2020 Farmer's Business Network, Inc. All rights reserved. The sprout logo, “Farmers Business Network”, “FBN”, “Farmers First” and the Farmers First flag logo are registered service marks of Farmer’s Business Network, Inc. All other marks are the property of their respective owners.
Copyright ©2020 GRO Network. All rights reserved. “GRO Network” and the GRO Network logo are registered trademarks of GRO Network.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005290/en/
Contact information
Media:
Keith Chapman
Chap Public Relations
Keith@chappublicrelations.com
847-970-2171
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
